Pfizer India: First quarter of Wyeth consolidation - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

StockSelect
  • MyStocks
MEMBER'S LOGIN

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • Jul 16, 2015 - Pfizer India: First quarter of Wyeth consolidation

Pfizer India: First quarter of Wyeth consolidation

Jul 16, 2015 | Updated on Oct 30, 2019

Pfizer India has announced its 4QFY15 results. The company has reported an 81.3% YoY growth in net sales and a decline of 23.8% YoY in net profits. Here is our analysis of the results.

Performance summary
  • Net sales were up by 81.3% YoY. The operating margins stood at 26.9% for the quarter. The net profits were down by 23.8% YoY.
  • Please note, this is the first quarter post amalgamation with Wyeth, hence the financials are not comparable. In the subsequent paragraphs, we will discuss the adjusted growth and key highlights in this consolidation.

Financial performance: A snapshot
(Rs m) 4QFY14 4QFY15 Change FY14 FY15 Change
Net sales 2,517 4,563 81.3% 10,043 18,277 82.0%
Other operating income 228 68 -70.2% 1,075 256 -76.2%
Expenditure 2,016 3,383 67.8% 8,733 14,703 68.4%
Operating profit (EBDITA) 729 1,248 71.1% 2,385 3,830 60.6%
EBDITA margin (%) 26.6% 26.9%   21.5% 20.7%  
Other income 163 188 15.1% 1,094 674 -38.4%
Interest (net) 1.9 1.7 -10.5% 4 8 113.9%
Depreciation 20 336 1557.1% 80 1,311  
Profit before tax 870 1,097 26.1% 3,396 3,185 -6.2%
Exceptional Item - -   - (804)  
Tax 310 671 116.5% 1,188 1,377 15.9%
Profit after tax/(loss) 560 427 -23.8% 2,208 1,004 -54.5%
Net profit margin (%) 20.4% 9.2%   22.0% 5.5%  
No. of shares (m)       29.8 29.8  
Diluted earnings per share (Rs)         34.8  
Price to earnings ratio (x)*         60.8  
* On a trailing 12 months basis

What has driven performance in 4QFY15 and FY15?
  • On like to like basis, Pfizer’s sales including Wyeth for the full year grew by 12% YoY. One of Pfizer’s key products Corex (Codeine) has been facing regulatory challenges in some geographies in India. This had impacted the sales for the quarter. Excluding Corex, the growth is 14% YoY. For the quarter, the growth was 6% YoY for Pfizer. This was largely driven by Gelusil, which was promoted through credit schemes.

  • The EBITDA margins for the year stood at 21% on a like to like basis.

  • Further, excluding the incremental impact of depreciation of approx Rs 1,180 m for the year and VRS related costs of Rs 800 m, the bottom line has grown by 17% YoY.

  • Post amalgamation, the equity share capital for Pfizer has increased to 45.7 m shares from 29.8 m shares. This is post Pfizer allotted 15.9 m shares to Wyeth shareholders.
What to expect?

At the current price of Rs 2,116 the stock is trading at a multiple of 24 times our estimated FY17 earnings.

Since some time, the growth of MNC pharma companies has remained under pressure. However, the performance improved during the quarter. As per IMS data, the MNC pharma pack grew by 7.8% in March 2015.

Post consolidation with Wyeth, Pfizer will be able to benefit from a better portfolio.

However, since the Indian government is aggressively taking steps to bring drugs under pricing regulations, this can have negative impact. We shall soon update our FY18 estimates and target price for the company. Till then, investors can continue to Hold on to the stock of Pfizer.

We would like to gently remind you that your allocation to equities should be decided upon after keeping aside some safe cash. Also within your overall exposure to equities please ensure that you broadly follow suggested asset allocation and that no single stock comprises 5% of your portfolio.

To Read the Full Story, Subscribe or Sign In
To Read the Full Story, Subscribe or Sign In



DISCLOSURES UNDER SEBI (RESEARCH ANALYSTS) REGULATIONS, 2014
INTRODUCTION:
Equitymaster Agora Research Private Limited (hereinafter referred to as "Equitymaster"/"Company") was incorporated on October 25, 2007. Equitymaster is a joint venture between Quantum Information Services Private Limited (QIS) and Agora group. Equitymaster is a SEBI registered Research Analyst under the SEBI (Research Analysts) Regulations, 2014 with registration number INH000000537.

BUSINESS ACTIVITY:
An independent research initiative, Equitymaster is committed to providing honest and unbiased views, opinions and recommendations on various investment opportunities across asset classes.

DISCIPLINARY HISTORY:
There are no outstanding litigations against the Company, it subsidiaries and its Directors.

GENERAL TERMS AND CONDITIONS FOR RESEARCH REPORT:
For the terms and conditions for research reports click here.

DETAILS OF ASSOCIATES:
Details of Associates are available here.

DISCLOSURE WITH REGARDS TO OWNERSHIP AND MATERIAL CONFLICTS OF INTEREST:
  1. Neither Equitymaster, it's Associates, Research Analyst or his/her relative have any financial interest in the subject company.
  2. Neither Equitymaster, it's Associates, Research Analyst or his/her relative have actual/beneficial ownership of one percent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.
  3. Neither Equitymaster, it's Associates, Research Analyst or his/her relative have any other material conflict of interest at the time of publication of the research report.
DISCLOSURE WITH REGARDS TO RECEIPT OF COMPENSATION:
  1. Neither Equitymaster nor it's Associates have received any compensation from the subject company in the past twelve months.
  2. Neither Equitymaster nor it's Associates have managed or co-managed public offering of securities for the subject company in the past twelve months.
  3. Neither Equitymaster nor it's Associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.
  4. Neither Equitymaster nor it's Associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months.
  5. Neither Equitymaster nor it's Associates have received any compensation or other benefits from the subject company or third party in connection with the research report.
GENERAL DISCLOSURES:
  1. The Research Analyst has not served as an officer, director or employee of the subject company.
  2. Equitymaster or the Research Analyst has not been engaged in market making activity for the subject company.
Definitions of Terms Used:
  1. Buy recommendation: This means that the investor could consider buying the concerned stock at current market price keeping in mind the tenure and objective of the recommendation service.
  2. Hold recommendation: This means that the investor could consider holding on to the shares of the company until further update and not buy more of the stock at current market price.
  3. Buy at lower price: This means that the investor should wait for some correction in the market price so that the stock can be bought at more attractive valuations keeping in mind the tenure and the objective of the service.
  4. Sell recommendation: This means that the investor could consider selling the stock at current market price keeping in mind the objective of the recommendation service.
Feedback:
If you have any feedback or query or wish to report a matter, please do not hesitate to write to us.

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2021
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

PFIZER SHARE PRICE


Jun 25, 2021 03:35 PM

TRACK PFIZER

MORE ON PFIZER

PFIZER - OMKAR PHARMACHEM COMPARISON

Compare Company With Charts

COMPARE PFIZER WITH

FEATURED VIDEOS

CRISIL v/s CARE Ratings: An Interesting Comparison

The 3-Word Secret to Earning Incredible Returns

Buy & Hold v/s In & Out Investing

An Investing System that Found 20 Winners in a Row

More Featured Videos

MARKET STATS


ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
FOLLOW
  • Follow on LinkedIn Follow @Equitymaster Follow on RSS Follow on Telegram

APP
  • Get Equitymaster Android App on Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.